TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is safe and effective. These finding are of crucial importance to the definite adoption of TAVR in the lower risk, younger population. 

durabilidad del TAVI pasa a un segundo plano con los resultados del TRANSIT

Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in severe aortic stenosis treatment.  Technological innovation and growing expertise have allowed to significantly reduce adverse events compared to the early days of TAVR. 

However, durability was, or still is, a question to be answered over time. After this registry outcomes, TAV durability becomes irrelevant, since they provide the solution to this problem. 

Researchers from 28 centers around the world included 172 TAVR patients receiving a second TAVR for degenerated first TAV (33%), regurgitant TAV (56%) or a combination of both (11%). Most patients (73.5%) were in functional class III-IV.

According to VARC 2 criteria (Valve Academic Research Consortium 2) procedural success rate was 79% as a consequence of 14% residual gradient and 7% regurgitation. 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


All-cause mortality one year after the second procedure resulted 10% while new hospitalization and functional class III-IV rates resulted 7.6% and 5.8% respectively. There were no significant differences between subgroups.

There were no valve thrombosis cases.

Conclusion

Transcatheter implantation of a second prosthesis in select patients with degenerated or regurgitant TAVs is feasible, and has high success and low complications rates. 

Original Title: Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project.

Reference: Luca Testa et al. Circ Cardiovasc Interv. 2021 Jun;14(6):e010440. doi: 10.1161/CIRCINTERVENTIONS.120.010440.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Impact of Iliofemoral Disease on Post TAVR Clinical Outcomes: HOSTILE Score Validation

At present, transcatheter aortic valve replacement (TAVR) has been shown safe and effective for treating severe symptomatic aortic stenosis in high-surgical-risk patients. Moreover, its...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...